Why the study?
Does BMI > 25 increase toxicity or affect prognosis in women with lung cancer receiving carboplatin-paclitaxel chemotherapy?
Does BMI > 25 increase toxicity or affect prognosis in women with lung cancer receiving carboplatin-paclitaxel chemotherapy?
Overweight and obese women with lung cancer receiving carboplatin-paclitaxel do not have an increased risk of toxicity when appropriate dose reductions are applied.
Supports similar survival and toxicity across BMI groups with dose adjustments; leaves open prospective validation in lung cancer.
We retrospectively analyzed overdosing-related toxicity and prognosis in 127 women with lung cancer receiving carboplatin (6AUC) estimated by the Cockcroft-Gault formula using actual body weight and paclitaxel (200 mg/m(2)). Between the body mass index (BMI) > 25 group (n = 42) and the BMI ≤ 25 group (n = 85), there was no difference in dose intensity of carboplatin (122 mg/m(2)/week vs. 124 mg/m(2)/week, p = .323), median overall survival (285 days vs. 282 days, p = .820), and toxicity, except Grade 4 neutropenia in the second cycle. Women with BMI > 25 did not have an increased risk of toxicity because of an appropriate dose reduction.
No takes yet. Share an insight, caveat, or question.
Kashiwabara et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: